These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 32988758)

  • 1. COVID 19 and liver: An A-Z literature review.
    Metawea MI; Yousif WI; Moheb I
    Dig Liver Dis; 2021 Feb; 53(2):146-152. PubMed ID: 32988758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver injury in COVID-19: The current evidence.
    Alqahtani SA; Schattenberg JM
    United European Gastroenterol J; 2020 Jun; 8(5):509-519. PubMed ID: 32450787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 and liver disease.
    Sun J; Aghemo A; Forner A; Valenti L
    Liver Int; 2020 Jun; 40(6):1278-1281. PubMed ID: 32251539
    [No Abstract]   [Full Text] [Related]  

  • 4. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.
    Wang Y; Liu S; Liu H; Li W; Lin F; Jiang L; Li X; Xu P; Zhang L; Zhao L; Cao Y; Kang J; Yang J; Li L; Liu X; Li Y; Nie R; Mu J; Lu F; Zhao S; Lu J; Zhao J
    J Hepatol; 2020 Oct; 73(4):807-816. PubMed ID: 32437830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver injury in the era of COVID-19.
    Cichoż-Lach H; Michalak A
    World J Gastroenterol; 2021 Feb; 27(5):377-390. PubMed ID: 33584070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy.
    Shiri Aghbash P; Ebrahimzadeh Leylabadlo H; Fathi H; Bahmani M; Chegini R; Bannazadeh Baghi H
    Can J Gastroenterol Hepatol; 2022; 2022():4291758. PubMed ID: 36531832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel.
    Napodano C; Pocino K; Stefanile A; Marino M; Miele L; Gulli F; Basile V; Pandolfi F; Gasbarrini A; Rapaccini GL; Basile U
    Scand J Immunol; 2021 Mar; 93(3):e12977. PubMed ID: 32931622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 and comorbidities of hepatic diseases in a global perspective.
    Ahmad A; Ishtiaq SM; Khan JA; Aslam R; Ali S; Arshad MI
    World J Gastroenterol; 2021 Apr; 27(13):1296-1310. PubMed ID: 33833483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 and hepatitis.
    Trevenzoli M; Guarnaccia A; Alberici I; Fassan M; Di Meco E; Farinati F; Cattelan AM
    J Gastrointestin Liver Dis; 2020 Sep; 29(3):473-475. PubMed ID: 32919428
    [No Abstract]   [Full Text] [Related]  

  • 10. A brief review of liver injury in patients with Corona Virus Disease-19 during the pandemic.
    Farshidpour M; Kim D; Junna S; Merchant J
    Indian J Gastroenterol; 2020 Jun; 39(3):232-235. PubMed ID: 32621206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic involvement in COVID-19 patients: Pathology, pathogenesis, and clinical implications.
    Li Y; Xiao SY
    J Med Virol; 2020 Sep; 92(9):1491-1494. PubMed ID: 32369204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver injury in severe COVID-19 infection: current insights and challenges.
    Ali N; Hossain K
    Expert Rev Gastroenterol Hepatol; 2020 Oct; 14(10):879-884. PubMed ID: 32649840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 and liver disease: An update.
    Téllez L; Martín Mateos RM
    Gastroenterol Hepatol; 2020 Oct; 43(8):472-480. PubMed ID: 32727662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same.
    Olry A; Meunier L; Délire B; Larrey D; Horsmans Y; Le Louët H
    Drug Saf; 2020 Jul; 43(7):615-617. PubMed ID: 32514859
    [No Abstract]   [Full Text] [Related]  

  • 15. Liver injury in COVID-19: clinical features and treatment management.
    Yu D; Du Q; Yan S; Guo XG; He Y; Zhu G; Zhao K; Ouyang S
    Virol J; 2021 Jun; 18(1):121. PubMed ID: 34108015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and cellular mechanisms of liver dysfunction in COVID-19.
    Huang C; Li Q; Xu W; Chen L
    Discov Med; 2020; 30(160):107-112. PubMed ID: 33382966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of ACEI/ARB, inflammatory cytokines, and antiviral drugs with liver dysfunction in patients with hypertension and COVID-19.
    Xiang D; Ren X; Chen Q; Yu H; Li X; Liu D
    Clin Exp Hypertens; 2021 May; 43(4):305-310. PubMed ID: 33356606
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management.
    Xu Y; Yang X; Bian H; Xia M
    Lipids Health Dis; 2021 Oct; 20(1):126. PubMed ID: 34602072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic consequences of COVID-19 infection. Lapping or biting?
    Portincasa P; Krawczyk M; Machill A; Lammert F; Di Ciaula A
    Eur J Intern Med; 2020 Jul; 77():18-24. PubMed ID: 32507608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement.
    Wong GL; Wong VW; Thompson A; Jia J; Hou J; Lesmana CRA; Susilo A; Tanaka Y; Chan WK; Gane E; Ong-Go AK; Lim SG; Ahn SH; Yu ML; Piratvisuth T; Chan HL;
    Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):776-787. PubMed ID: 32585136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.